
---
title: '癌症疫苗知多少'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://picsum.photos/400/300?random=2852'
author: 科学网
comments: false
date: Sat, 24 Apr 2021 10:01:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=2852'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;">癌症疫苗知多少</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">据世卫组织（</span><a href="https://www.who.int/features/factfiles/cancer/en/" target="_blank">WHO</a><span style="font-size: 18px; font-family: 宋体;">）网站报道，世界死亡人数中有</span>16%<span style="font-size: 18px; font-family: 宋体;">是与癌症有关，即在</span>6<span style="font-size: 18px; font-family: 宋体;">名死亡者中就约有一名死于癌症。大约</span>70%<span style="font-size: 18px; font-family: 宋体;">的癌症死亡者发生在中低收入国家；男性患癌风险高于女性，男性死于癌症的前</span>5<span style="font-size: 18px; font-family: 宋体;">种癌症分别为肺癌、肝癌、胃癌、结直肠癌以及前列腺癌。女性死于癌症的前</span>5<span style="font-size: 18px; font-family: 宋体;">种癌症分别为肺癌、乳腺癌、结直肠癌、宫颈癌以及胃癌。戒烟可以预防癌症，癌症</span>30%~50%<span style="font-size: 18px; font-family: 宋体;">是可以预防的，所有因癌症死亡人数中大约有</span>22%<span style="font-size: 18px; font-family: 宋体;">与吸烟有关。接种疫苗抗癌，如人乳头瘤病毒（</span>HPV<span style="font-size: 18px; font-family: 宋体;">）会引起宫颈癌，乙肝病毒（</span>HBV<span style="font-size: 18px; font-family: 宋体;">）会诱发肝癌，这两种病毒均可通过接种疫苗进行预防，通过接种疫苗每年可以预防</span>110<span style="font-size: 18px; font-family: 宋体;">万人患癌。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据《科学家》（</span><a href="https://www.omagdigital.com/publication/?i=702237&article_id=3990405&view=articleBrowser" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">The Scientist</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）网站</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>4<span style="font-size: 18px; font-family: 宋体;">月</span>16<span style="font-size: 18px; font-family: 宋体;">日报道——“癌症疫苗：组建</span>T<span style="font-size: 18px; font-family: 宋体;">细胞大军（</span></span><a href="https://www.the-scientist.com/sponsored-infographics/cancer-vaccines-raising-a-t-cell-army-68625" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">Cancer Vaccines: Raising a T Cell Army<span style="font-size: 18px; font-family: 宋体; color: windowtext;">）”介绍</span></span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">，科学家正在开发治疗癌症的疫苗，而不仅仅是为了预防癌症，对疫苗靶点和递送系统的研究也很广泛。大多数正在研究的疫苗都能促使</span> T <span style="font-size: 18px; font-family: 宋体;">细胞攻击并杀死癌细胞，但由于肿瘤可以逃避免疫系统，因此可能需要联合治疗以引起足够的免疫反应。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>1. T</strong><strong><span style="font-size: 18px; font-family: 宋体;">细胞启动（</span>T Cell Priming</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">T<span style="font-size: 18px; font-family: 宋体;">细胞由三个输入启动，以识别其靶标并对其靶标起作用。装备好后，效应</span>T<span style="font-size: 18px; font-family: 宋体;">细胞就可以响应并杀死靶标细胞。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>1.1 T</strong><strong><span style="font-size: 18px; font-family: 宋体;">细胞受体参与（</span>T cell receptor engagement</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">抗原呈递细胞（</span>antigen-presenting cell<span style="font-size: 18px; font-family: 宋体;">简称</span>APC<span style="font-size: 18px; font-family: 宋体;">）从靶标（癌细胞或病原体）收集肽，将其与主要组织相容性复合物（</span>major-histocompatibility complex<span style="font-size: 18px; font-family: 宋体;">简称</span>MHC<span style="font-size: 18px; font-family: 宋体;">）结合，然后将其呈递给幼稚</span>T<span style="font-size: 18px; font-family: 宋体;">细胞（</span>naïve T cells<span style="font-size: 18px; font-family: 宋体;">）。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>1.2 </strong><strong><span style="font-size: 18px; font-family: 宋体;">共同刺激（</span>Co-stimulation</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">抗原呈递细胞（</span>APC<span style="font-size: 18px; font-family: 宋体;">）向</span>T<span style="font-size: 18px; font-family: 宋体;">细胞呈递其他配体，例如</span>CD28<span style="font-size: 18px; font-family: 宋体;">。没有共刺激结合，</span>T<span style="font-size: 18px; font-family: 宋体;">细胞将不会被激活。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>1.3 </strong><strong><span style="font-size: 18px; font-family: 宋体;">细胞因子引起的炎症刺激（</span>Inflammatory stimulus from cytokines</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">细胞因子，例如干扰素（</span>interferons<span style="font-size: 18px; font-family: 宋体;">）或白介素（</span>interleukins<span style="font-size: 18px; font-family: 宋体;">），支持</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的刺激、扩增和分化。没有适当的细胞因子刺激，增殖的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞可能会死亡，从而导致免疫系统对刺激性抗原产生耐受性。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2. </strong><strong><span style="font-size: 18px; font-family: 宋体;">癌症疫苗目标（</span>Cancer Vaccine Targets</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2.1 </strong><strong><span style="font-size: 18px; font-family: 宋体;">肿瘤相关抗原（</span>Tumor-Associated Antigens</strong><strong><span style="font-size: 18px; font-family: 宋体;">简称</span>TAAs</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">肿瘤相关抗原（</span>TAA<span style="font-size: 18px; font-family: 宋体;">），例如前列腺特异性抗原（</span>prostate specific antigen<span style="font-size: 18px; font-family: 宋体;">简称</span>PSA<span style="font-size: 18px; font-family: 宋体;">），是在癌细胞中异常表达的正常宿主蛋白（</span>normal host proteins<span style="font-size: 18px; font-family: 宋体;">）。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2.1.1</strong><strong> </strong><strong><span style="font-size: 18px; font-family: 宋体;">优点（</span>Advantages</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•经过充分研究（</span>Well-researched<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•一些临床试验显示阳性反应（</span>Some clinical trials have shown positive responses<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•可与联合疗法配合使用（</span>May work well with combination therapies<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2.1.2</strong><strong> </strong><strong><span style="font-size: 18px; font-family: 宋体;">缺点（</span>Disadvantages</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•</span>T<span style="font-size: 18px; font-family: 宋体;">细胞对宿主蛋白的耐受性可能使其免疫原性较差</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•肿瘤相关抗原（</span>TAA<span style="font-size: 18px; font-family: 宋体;">）不是癌细胞专有的，因此它们可能引发自身免疫毒性</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在设计疫苗时，科学家考虑要靶向的抗原，但是理想的靶标很难找到。科学家们在癌症中异常表达的宿主蛋白或癌症特异性蛋白（</span>cancerspecific proteins<span style="font-size: 18px; font-family: 宋体;">）之间进行选择。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2.2 </strong><strong><span style="font-size: 18px; font-family: 宋体;">理想目标（</span>The Ideal Target</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">1<span style="font-size: 18px; font-family: 宋体;">）</span> <span style="font-size: 18px; font-family: 宋体;">在癌细胞上独家表达（</span>Exclusively expressed on cancer cells<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">2<span style="font-size: 18px; font-family: 宋体;">）</span> <span style="font-size: 18px; font-family: 宋体;">癌细胞生存所必需的，这样细胞就不能下调它（</span>Necessary for cancer cell survival, so that cells cannot downregulate it<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">3<span style="font-size: 18px; font-family: 宋体;">）</span> <span style="font-size: 18px; font-family: 宋体;">从未在宿主细胞上表达（</span>Never expressed on the host cells<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">4<span style="font-size: 18px; font-family: 宋体;">）</span> <span style="font-size: 18px; font-family: 宋体;">高免疫原性（</span>Highly immunogenic<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2.2.1</strong><strong> </strong><strong><span style="font-size: 18px; font-family: 宋体;">新抗原（</span>Neoantigens</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">新抗原，也称为新表位（</span>neoepitopes<span style="font-size: 18px; font-family: 宋体;">）或肿瘤特异性抗原（</span>tumor-specific antigens<span style="font-size: 18px; font-family: 宋体;">简称</span>TSA<span style="font-size: 18px; font-family: 宋体;">），是通过癌细胞突变产生的蛋白质产生的肽。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2.2.2</strong><strong> </strong><strong><span style="font-size: 18px; font-family: 宋体;">优点（</span>Advantages</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">•易于通过健康和肿瘤组织的下一代测序进行鉴定</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•新算法可预测抗原是否为良好的主要组织相容性复合体</span>I<span style="font-size: 18px; font-family: 宋体;">类结合表位（</span>MHC class I-binding epitope<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•癌细胞专有，因此它们不会诱导</span>T<span style="font-size: 18px; font-family: 宋体;">细胞耐受</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>2.2.3</strong><strong> </strong><strong><span style="font-size: 18px; font-family: 宋体;">缺点（</span>Disadvantages</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•从多个患者中测序肿瘤</span>DNA<span style="font-size: 18px; font-family: 宋体;">既昂贵又缓慢</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">•制造缓慢</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">•专家之间在如何识别引发免疫反应的新抗原方面没有共识</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">•突变负荷低的癌症的候选抗原很少</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>3 </strong><strong><span style="font-size: 18px; font-family: 宋体;">新抗原的类型（</span>Types of Neoantigens</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>3.1 </strong><strong><span style="font-size: 18px; font-family: 宋体;">热点突变</span>(Hotspot Mutations)</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">•许多癌症患者表达相同的新抗原</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•可用于生产“现成”疫苗</span>(<span style="font-size: 18px; font-family: 宋体;">“</span>off-the-shelf<span style="font-size: 18px; font-family: 宋体;">”</span> vaccines)</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>3.2 </strong><strong><span style="font-size: 18px; font-family: 宋体;">致癌病毒抗原（</span>Oncogenic Viral Antigens</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•病毒感染可能占癌症的</span>10<span style="font-size: 18px; font-family: 宋体;">％</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•由病毒驱动的肿瘤表达病毒蛋白（</span>viral proteins<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">•确定良好的疫苗靶标，因为它们具有高度免疫原性（</span>highly immunogenic<span style="font-size: 18px; font-family: 宋体;">）</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">•通常用于制造常规预防性疫苗</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4 </strong><strong><span style="font-size: 18px; font-family: 宋体;">提供癌症治疗疫苗（</span>Delivery of Cancer Treatment Vaccines</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.1 </strong><strong><span style="font-size: 18px; font-family: 宋体;">免疫细胞疫苗（</span>Immune Cell Vaccines</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这些疫苗使用患者或细胞培养来源的免疫细胞。它们通常由掺入靶抗原的抗原呈递细胞（</span>APC<span style="font-size: 18px; font-family: 宋体;">）制成。抗原呈递细胞如树突细胞（</span>dendritic cells<span style="font-size: 18px; font-family: 宋体;">简称</span>DC<span style="font-size: 18px; font-family: 宋体;">）。重新引入患者后，它们会刺激</span>T<span style="font-size: 18px; font-family: 宋体;">细胞扩增和分化。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">有一些批准的免疫细胞疫苗，但是由于缺乏积极的结果，许多疫苗在临床试验中被取消了。但是，科学家可以将它们用于联合疗法。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.2 </strong><strong><span style="font-size: 18px; font-family: 宋体;">患者源性免疫细胞疫苗（</span>Patient-Derived Immune Cell Vaccines</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">科学家收获患者的免疫细胞，在实验室中诱导抗原摄取，然后将其重新引入体内。这是一个昂贵且耗时的过程。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.3 </strong><strong><span style="font-size: 18px; font-family: 宋体;">肿瘤细胞系的全细胞疫苗（</span>Whole Cell Vaccine From Tumor Cell Lines</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">研究人员从肿瘤细胞系中开发出现成的疫苗，以便快速开发出治疗方法。例如，用于胰腺癌的</span>Algenpantucel-L<span style="font-size: 18px; font-family: 宋体;">是由致命辐照细胞（</span>lethally irradiated cells<span style="font-size: 18px; font-family: 宋体;">）制成的。注射后，患者树突细胞（</span>DCs<span style="font-size: 18px; font-family: 宋体;">）吸收这些细胞并向淋巴结中的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞展示肿瘤抗原。该疫苗的临床试验结果非常肯定，无病生存率（</span>disease-free survival rate<span style="font-size: 18px; font-family: 宋体;">）几乎翻了一番。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.4 </strong><strong><span style="font-size: 18px; font-family: 宋体;">基于肿瘤裂解物的疫苗（</span>Tumor Lysate-Based Vaccines</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">研究人员在重新注射之前，将从患者身上分离出的树突细胞（</span>DCs<span style="font-size: 18px; font-family: 宋体;">）暴露于肿瘤裂解液中。无需测序或计算即可确定免疫原性。但是，大多数抗原是肿瘤相关抗原（</span>TAA<span style="font-size: 18px; font-family: 宋体;">）或非免疫原性自身抗原（</span>non-immunogenic self antigens<span style="font-size: 18px; font-family: 宋体;">）。重新注入的树突细胞（</span>DCs<span style="font-size: 18px; font-family: 宋体;">）很少显示新抗原，并且大多数最终不能刺激</span>T<span style="font-size: 18px; font-family: 宋体;">细胞反应。科学家可以在设计和生产个性化新抗原疫苗时使用这种方法作为初免疫苗。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.5 </strong><strong><span style="font-size: 18px; font-family: 宋体;">重组病毒载体疫苗</span>(Recombinant viral vector vaccines)</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">表达肿瘤抗原的重组病毒是通过直接注射施用的现成疫苗。与常规疫苗相似，重组病毒疫苗毒性低。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.6 </strong><strong><span style="font-size: 18px; font-family: 宋体;">肽疫苗</span>(Peptide vaccines)</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这些疫苗是</span>20-30<span style="font-size: 18px; font-family: 宋体;">个肿瘤特异性肽的集合，这些肽通常长</span>15<span style="font-size: 18px; font-family: 宋体;">个氨基酸。使用该技术的临床试验未能在第三阶段取得结果，但它们可能会从联合疗法中获益。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.7 RNA</strong><strong><span style="font-size: 18px; font-family: 宋体;">和</span>DNA</strong><strong><span style="font-size: 18px; font-family: 宋体;">疫苗（</span>RNA and DNA vaccines</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">RNA<span style="font-size: 18px; font-family: 宋体;">和</span>DNA<span style="font-size: 18px; font-family: 宋体;">疫苗提供详细的设计和递送参数。它们可以整合用于</span>T<span style="font-size: 18px; font-family: 宋体;">细胞诱导，自我佐剂（</span>selfadjuvants<span style="font-size: 18px; font-family: 宋体;">）或自我复制的基因，以增强免疫反应。</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">疫苗的快速部署大部分归功于</span>RNA<span style="font-size: 18px; font-family: 宋体;">癌疫苗研究。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.8 </strong><strong><span style="font-size: 18px; font-family: 宋体;">组合疗法（</span>Combination Therapies</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">临床试验中的许多癌症治疗疫苗效果不佳。然而，使用联合疗法从多个方面攻击癌症的乐观性很高。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.9 </strong><strong><span style="font-size: 18px; font-family: 宋体;">免疫刺激剂（</span>Immunostimulators</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">与诸如细胞因子和佐剂的分子共同处理可以增强免疫反应。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.10 </strong><strong><span style="font-size: 18px; font-family: 宋体;">常规化学疗法或放射疗法（</span>Conventional chemo- or radiotherapies</strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">常规疗法可通过引起局部炎症和癌细胞死亡来帮助抗原提呈细胞（</span>APCs<span style="font-size: 18px; font-family: 宋体;">）看到癌症。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>4.11 </strong><strong><span style="font-size: 18px; font-family: 宋体;">免疫检查点疗法</span>(Immune checkpoint therapy)</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">癌症治疗疫苗的最大突破之一是免疫检查点抑制剂（</span>immune checkpoint inhibitors<span style="font-size: 18px; font-family: 宋体;">简称</span>ICI<span style="font-size: 18px; font-family: 宋体;">）的鉴定。通常，免疫系统在清除入侵的病原体后会自行关闭。一些癌症已经进化出过表达和分泌告诉</span>T<span style="font-size: 18px; font-family: 宋体;">细胞停下来的免疫检查点抑制剂的能力。用抗体阻断</span>ICI<span style="font-size: 18px; font-family: 宋体;">可防止它们干扰</span>T<span style="font-size: 18px; font-family: 宋体;">细胞反应。上述介绍，仅供参考，更多信息请注意浏览<a href="https://www.omagdigital.com/publication/?i=702237&article_id=3990405&view=articleBrowser" target="_blank">相关报道</a>。</span></span><a href="https://www.the-scientist.com/sponsored-infographics/cancer-vaccines-raising-a-t-cell-army-68625" target="_blank" style="font-size: 18px; font-family: "times new roman";">Cancer Vaccines: Raising a T Cell Army</a></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1283500.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1283500.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1282965.html" target="_black">DNA纳米机器人的设计仅仅需要几分钟而并非几天</a><br>                    <!--大赛结束-->
                                        
  
</div>
            